A 30-year-old woman given a diagnosis of stage IV lung adenocarcinoma, was admitted to our hospital because of chest pain due to pleuritis carcinomatosa. She had taken uracil/tegafur (UFT) 600 mg orally every day from September 2004. Uracil/tegafur was stopped in December 10, 2005, and docetaxel (taxotere) 50 mg/m² was given in December 12, 2005. Seven days after treatment with docetaxel she developed erythema and spontaneous pain of the palms and fingers of both hands and soles of both feet. The erythema increased gradually, and 10 days after docetaxel infusion she could not walk due to severe pain. After improvement of the painful erythema, desquamation of fingers of both hands and the soles of both feet occurred. She was diagnosed with hand-foot syndrome. Although the same amount of docetaxel was given later, hand-foot syndrome was not seen. Therefore it was suggested that both uracil/tegafur and docetaxel induced hand-foot syndrome. Fluoropyrimidines and taxanes have been reported as common anti-cancer drugs that lead to hand-foot syndrome. Since these drugs play a crucial role in lung cancer treatment, we need to pay attention to hand-foot syndrome. A sufficient off-drug period is required in the sequential usage of fluoropyrimidines and taxanes.